Skip to main content
. 2004 Jul 10;329(7457):75. doi: 10.1136/bmj.38125.465579.55

Table 1.

Characteristics and methodological quality of randomised trials in review

Katz, 199925 De Deyn, 199924 Chan, 200123 Brodaty, 200322 Street, 200026
Interventions Risperidone v placebo Risperidone v haloperidol v placebo Risperidone v haloperidol Risperidone v placebo Olanzapine v placebo
No of patients 625 (462 risperidone, 163 placebo) 344 (115 risperidone, 115 haloperidol, 114 placebo) 58 (29 risperidone, 29 haloperidol) 337 (167 risperidone, 170 placebo) 206 (159 olanzapine, 47 placebo)
Drug dose (per day) Fixed: 0.5, 1, or 2 mg Flexible: mean 1.1 mg risperidone, 1.2 mg haloperidol Flexible: mean 0.85 mg risperidone, 0.9 mg haloperidol Flexible: mean 0.95 mg Fixed: 5, 10, or 15 mg
Duration (weeks) 12 12 12 12 6
Mean age (years) 82.6 81.3 80.5 83.0 82.8
Diagnosis 73% AD, 15% VaD, 11% mixed 67% AD, 26% VaD, 7% mixed 79% AD, 21% VaD 58% AD, 29% VaD, 13% mixed 100% AD
Mean MMSE (out of 30)27 6.6 8.4 8.0 5.5 6.7
Assessment of quality:
Randomisation* 1 2 1 1 2
Blinding 2 2 1 2 2
Withdrawals/dropouts 1 1 1 1 1
Jadad quality score§ 4 5 3 4 5
Concealment 0 1 0 0 1
Follow up** 2 2 2 2 2

AD=Alzheimer's disease; MMSE=Folstein mini mental state examination; VaD=vascular dementia.

*

0=not randomised or pseudo-randomised; 1=randomised, method not described; 2=randomised, appropriate method reported.

0=no blinding or inappropriate method; 1=double blind, blinding not reported; 2=double blind, blinding appropriate.

0=not described for each group; 1=described by group.

§

Score out of 5, based on scores for randomisation, blinding, and withdrawals/dropouts; does not consider concealment of allocation or adequacy of follow up.17

0=no concealment process described; 1=concealment process described.

**

0=no or inadequate reporting of follow up; 1=reported, data not analysed according to intention to treat; 2=reported, data analysed according to intention to treat.